IMPDH1 and neoplasm: Exogenous supplementation with mycophenolic acid (MPA), a drug that inhibits IMPDH1, suppresses the malignant phenotype of ICC, inhibits the secretion of inflammatory factors, and ultimately alleviates tumor growth in ICC.